



Attorney Docket No. 100718-5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SERIAL NO. : 08/849,525  
APPLICANT : Ghita Lanzendorfer  
FILED : August 29, 1997  
EXAMINER : Shahnam J. Sharareh  
ART UNIT : 1617  
FOR : USE OF FLAVONOIDS AS IMMUNOMODULATING OR  
IMMUNO-PROTECTIVE AGENTS IN COSMETIC AND  
DERMATOLOGICAL PREPARATIONS

---

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

October 21, 2005

**INFORMATION DISCLOSURE STATEMENT**

SIR:

Pursuant to 37 CFR §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the Examiner consider the references listed on the attached Form PTO/SB/08.

**I. Timeliness, Fees and Certifications in lieu of Fees**

☒ A. This information disclosure statement is being filed within three months of the filing date of the application, or within three months of entry into the national stage, or before the mailing of a first Office Action on the merits. Pursuant to 37 CFR § 1.97(b), consideration of this information disclosure statement does not require a fee or a statement under 37 CFR § 1.97(e). However, should the Assistant Commissioner determine that a fee is, in fact, due, the Assistant Commissioner is hereby authorized to charge the fee to Deposit Account No. 14-1263.

☐ B. This information disclosure statement is being filed after the period in A above, but before the mailing of either a final action or a notice of allowance. Pursuant to 37 CFR §

1.97(c), consideration of this information disclosure statement requires a fee or a statement under 37 CFR § 1.97(e):

- ☐ 1. The Assistant Commissioner is hereby authorized to charge the fee set forth in 37 CFR § 1.17(p) to Deposit Account No. 14-1263.
- ☐ 2. Applicants hereby state that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.
- ☐ 3. Applicants hereby state that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 CFR § 1.56 more than three months prior to the filing of this information disclosure statement.
- ☐ C. This information disclosure statement is being filed after the period specified in B above, but on or before the payment of the issue fee. Pursuant to 37 CFR § 1.97(d), consideration of this information disclosure statement requires a petition, which Applicants hereby request, and payment of the petition fee, which is set forth in 37 CFR § 1.17(i), and which the Assistant Commissioner is hereby authorized to charge to Deposit Account No. 14-1263. Consideration of this information disclosure statement also requires a statement under 37 CFR § 1.97(e):

- ☐ 1. Applicants hereby state that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.
- ☐ 2. Applicants hereby state that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent

office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 CFR § 1.56 more than three months prior to the filing of this information disclosure statement.

## **II. Copies of Listed References**

☒ A. Copies of all references listed on the attached Form PTO/SB/08 are being supplied. Copies of U.S. patents are not included pursuant to Pre-OG Notice dated July 11, 2003.

☐ B. Copies of all references listed on the attached Form PTO/SB/08 have already been supplied during the prosecution of prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, from which the present application claims priority pursuant to 35 USC § 120. Therefore, pursuant to 37 CFR § 1.98(d), copies of the references listed on the attached Form PTO/SB/08 are not now being supplied.

☐ C. This application is a PCT national stage application, all references listed on the attached Form PTO/SB/08 were cited in the international search report, and PCT/DO/EO/903 indicates that both the international search report and the copies of the references listed on the attached Form PTO/SB/08 are in this national stage file. Therefore, copies of the references listed on the attached Form PTO/SB/08 are not now being supplied.

## **III. Concise Statement of Relevance**

☐ A. All references listed on the attached Form PTO/SB/08 are in the English language, and, therefore, a concise statement of relevance is not required.

☐ B. All references listed on the attached Form PTO/SB/08 are cited in the European Search Reports, and a copy of that search report, which indicates the degree of relevance found by the European Search Authority, is attached.

☐ C. All references listed on the attached Form PTO/SB/08 were cited in the search report issued by the German Patent Office.

☒ D. This application is a PCT national stage application, all references listed on the attached Form PTO/SB/08 were cited in the international search report, and a copy of that search report, which indicates the degree of relevance found by the International Search Authority, is attached.

☐ E. All listed on the attached Form PTO/SB/08 were cited during the prosecution of the prior application indicated above under II.B.

#### **IV. Additional Information**

☐ A. In addition to the references listed on the attached Form PTO/SB/08, Applicants wish to bring to the attention of the Examiner the following abandoned or co-pending U.S. patent applications:


[Pursuant to 37 CFR § 1.98(a)(2)(iii), copies of these applications are not being submitted.]

☐ B. In addition of the references listed on the attached Form PTO/SB/08, Applicants wish to bring to the attention of the Examiner the information provided on the attached sheet.


Consideration of the foregoing in relation to this application is respectfully requested.

Respectfully submitted,

NORRIS McLAUGHLIN & MARCUS, P.A.

By 

Paul S. Lim  
Attorney for Applicant(s)  
Reg. No. 55,383  
875 Third Avenue - 18<sup>th</sup> Floor  
New York, New York 10022  
Phone: (212) 808-0700  
Fax: (212) 808-0844

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**
**Complete if Known**

Application Number	08/849,525
Filing Date:	August 29, 1997
First Named Inventor	Ghita Lanzendorfer et al.
Art Unit	1617
Examiner Name:	Shahnam J. Sharareh
Attorney Docket Number:	100718-5

Sheet 1

of 1

**U.S. PATENT DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup>	Publication Date MM-DD-YYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A				
	B				
	C				

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No.	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup>	Publication Date MM-DD-YYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		JP 1-96106 A	4-14-1989	Reiji Miyahara		
		JP 63-208506 A	8-30-1988	Kazuo Koyama		
		0 577 143 A2	01-05-1994	Jens-Christian Wunderlich		
		0 577 143 A3	01-05-1994	Jens-Christian Wunderlich		
		0 402 049 A2	12-12-1990	Hiromi Hijiya		
		0 387 042 A1	09-12-0990	Yukio Suzuki		
		GB 2 259 014 A	03-03-1993	Nira Hadas et al.		
		0 595 694 A1	05-04-0994	Quang Lan N'Guyen		
		2 699 818	07-01-1994	Quang Lan N'Guyen		
		0 496 649 A1	07-29-1992	Bernard Fabre		

**NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		XP-002236196	
		XP-002236195	

**EXAMINER SIGNATURE:****DATE CONSIDERED:**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>see Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>for Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.197 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or